Cyproheptadin Tablets BP 4 mg Exporter in India – Healthy Inc

Cyproheptadin Tablets BP 4 mg | Exporter
Product image for Cyproheptadin Tablets BP 4 mg Exporter; regulatory dossiers & international shipping.
Product Information
| Generic Name | Cyproheptadin |
|---|---|
| Manufacturer | Healthy Life Pharma Pvt. Ltd. |
| HSN Code | 30049099 |
| Pharmacopoeia | BP |
| Product Type | Tablet |
| Category | Antihistamine drugs |
| Subcategory | Antihistamine drugs |
| Active Ingredient | Cyproheptadin |
| Strength | 4 mg |
| Dosage Form | Tablet |
| Pack Size | 10 x 10 Tablets / Box (Alu-Alu / Blister) |
| Route of Administration | Oral |
| Prescription Required | Yes |
| Therapeutic Category | Antihistamine drugs |
Medicine Details & Safety
| Short Description | Healthy Inc invites international procurement enquiries for Cyproheptadin Tablets BP 4 mg manufactured by Healthy Life Pharma. Importers and overseas distributors can submit destination-country requirements for assessment of registration documentation, export artwork and shipment feasibility. | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Approved Uses / Indications | 1. Therapeutic management of indicated clinical conditions as authorized by clinical compendia. 2. Symptom control and maintenance therapy as part of comprehensive patient treatment regimens. | ||||||||||||||||||||||||
| Full Description | Healthy Inc invites international procurement enquiries for Cyproheptadin Tablets BP 4 mg manufactured by Healthy Life Pharma. Importers and overseas distributors can submit destination-country requirements for assessment of registration documentation, export artwork and shipment feasibility. Product technical specifications
Product technical specifications
Export regulatory and dossier readinessIdentify the destination authority and registration pathway. Request confirmation of CTD or ACTD dossier availability, COPP, Free Sale Certificate and current GMP documentation as applicable. Confirm COA and analytical files for the proposed product and market.Climatic zone stability and export artworkFor Cyproheptadin Tablets BP 4 mg, request stability evidence appropriate to the importing market, including Zone IVb where required. Confirm shelf life, storage conditions and multilingual carton, blister and leaflet artwork against approved documentation.Global logistics and trade termsSpecify the destination, shipment size and required delivery window. Evaluate air freight or LCL/FCL sea freight from Mumbai where feasible. Agree EXW, FOB, CIF or CIP as appropriate to the transport mode and contract; confirm freight, insurance and customs responsibilities.International buyer requirementsEnquiries may identify Africa, LATAM, Middle East, CIS or APAC as target regions. Market authorization, import permits, document availability and shipment acceptance must be confirmed for each country; this is not a statement of existing registrations. | ||||||||||||||||||||||||
| Dosage Instructions | Administer orally as directed by the prescribing physician. Swallow whole with water; adhere strictly to the recommended therapeutic regimen and schedule. | ||||||||||||||||||||||||
| Side Effects | Common: Mild nausea, headache, gastrointestinal discomfort, transient fatigue. Uncommon: Dizziness, dry mouth, mild cutaneous rash, loose stools. Rare: Severe allergic hypersensitivity, acute idiosyncratic reactions. | ||||||||||||||||||||||||
| Warnings and Precautions | Clinical Supervision: Use under qualified medical guidance. Organ Function Monitoring: Perform routine renal and hepatic evaluations during prolonged therapy. Disclose all concurrent medications, allergies, and medical history prior to treatment. | ||||||||||||||||||||||||
| Contraindications | 1. Known hypersensitivity to Cyproheptadin or tablet inactive ingredients. 2. Severe organ decompensation or acute metabolic crises. 3. Uncontrolled acute systemic disorders without specialized medical monitoring. | ||||||||||||||||||||||||
| Drug Interactions | 1. Concomitant prescription pharmaceuticals: Potential pharmacokinetic and pharmacodynamic interactions requiring physician review. 2. Central depressants or alcohol: May accentuate adverse neurological or sedative symptoms. 3. Over-the-counter supplements: Consult a clinician before combination. |
Frequently Asked Questions
| Question | Answer |
|---|---|
| Which registration documents can be requested for Cyproheptadin Tablets BP 4 mg? | Specify CTD/ACTD, COPP, FSC, COA and stability requirements for availability review. |
| Is Zone IVb data available for Cyproheptadin Tablets BP 4 mg? | Request confirmation for the exact formulation and packaging configuration. |
| Can export artwork be multilingual for Cyproheptadin Tablets BP 4 mg? | Provide the required languages and approved regulatory artwork for review. |
| Which shipping terms can be discussed for Cyproheptadin Tablets BP 4 mg? | EXW, FOB, CIF and CIP may be evaluated according to shipment mode and agreement. |
| How do I obtain an export quotation for Cyproheptadin Tablets BP 4 mg? | Provide destination country, quantity, documentation requirements and preferred trade terms. |
Related Products
✚
Cyproheptadin Tablets BP 4 mg ManufacturerView product →
✚
Cyproheptadin Tablets BP 4 mg SupplierView product →
✚
Cetrizine Tablets 10 mg ExporterView product →
✚
Cetrizine Tablets 10 mg ManufacturerView product →
✚
Cetrizine Tablets 10 mg SupplierView product →
✚
Chlorpheniramine Maleate Tablets IP 4 mg ExporterView product →
✚
Chlorpheniramine Maleate Tablets IP 4 mg ManufacturerView product →
✚
Chlorpheniramine Maleate Tablets IP 4 mg SupplierView product →
✚
Chlorpheniramine Maleate Tablets USP 4 mg ExporterView product →
✚
Chlorpheniramine Maleate Tablets USP 4 mg ManufacturerView product →
✚
Chlorpheniramine Maleate Tablets USP 4 mg SupplierView product →
✚
Cinnarizine Tablets 25 mg ExporterView product →
